At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 568 enrolled
Drug / intervention
Saxagliptin +1 moredrug
Likely dose
Saxagliptin 5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 24-Week International, Multi-centre, Randomized, Parallel-group, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of Saxagliptin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycaemic Control With Diet and Exercise.
In Brief
A Phase 3 clinical trial evaluating Saxagliptin and Placebo for Type 2 Diabetes. Completed, enrolled 568 participants across 30 sites in 4 countries.
Detailed Summary
Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to evaluate the efficacy and safety in adult patients with inadequate glycaemic control with diet and exercise.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesChina, India, Philippines, South Korea
CollaboratorsBristol-Myers Squibb
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2008
First PostedJun 2008
Primary CompletionOct 2009
TodayJul 2026
First PostedJun 17, 2008
Enrollment StartJun 1, 2008
Primary CompletionOct 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 18.0 years ago
Interventions
Saxagliptindrug
5mg, oral tablet, once daily for 24 weeks
Placebodrug
oral tablet, once daily for 24 weeks